4.6 Article

Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis

Journal

FRONTIERS IN MICROBIOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2022.1013439

Keywords

hepatitis B virus; acute-on-chronic liver failure; clinical prediction models; cirrhosis; performance

Categories

Funding

  1. National Key Research and Development Program of China [2021YFC2301800, 2017YFC0908100, 2017YFC0908103]
  2. Shanghai Hospital Development Commission [SHDC2020CR1037B]
  3. National Science and Technology Major Project [2018ZX10723203, 2017ZX10202202]
  4. National Natural Science Foundation of China [81930061, 81900579, 81473641, 81271884, 81461130019, 81700561, 81470038, 82070650, 81660333, 81870425]
  5. Chongqing Natural Science Foundation [CSTC2019jcyj-zdxmX0004]
  6. Department of Science and Technology of Guangdong Province [2015B020226004]
  7. Foundation for Innovative Research Groups of Natural Science Foundation of Hubei Province of China [2018CFA031]
  8. Shandong Province Natural Science Foundation [ZR2019PH052]
  9. 12-5 State S&T Projects of China [2018ZX10302-206]
  10. Fundamental Research Funds for the Central Universities
  11. Scientific Research Fund of Zhejiang University [XY2021030]

Ask authors/readers for more resources

The presence of underlying cirrhosis has a significant impact on the performance of clinical prediction models for predicting the outcome of HBV-ACLF. These models are more accurate in patients without cirrhosis, but are limited in patients with cirrhosis, possibly due to complications such as ascites or infections.
BackgroundThe accurate prediction of the outcome of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is impeded by population heterogeneity. The study aimed to assess the impact of underlying cirrhosis on the performance of clinical prediction models (CPMs). MethodsUsing data from two multicenter, prospective cohorts of patients with HBV-ACLF, the discrimination, calibration, and clinical benefit were assessed for CPMs predicting 28-day and 90-day outcomes in patients with cirrhosis and those without, respectively. ResultsA total of 919 patients with HBV-ACLF were identified by Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria, including 675 with cirrhosis and 244 without. COSSH-ACLF IIs, COSSH-ACLFs, Chronic Liver Failure-Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLFs), Tongji Prognostic Predictor Model score (TPPMs), Model for End-Stage Liver Disease score (MELDs), and MELD-Sodium score (MELD-Nas) were all strong predictors of short-term mortality in patients with HBV-ACLF. In contrast to a high model discriminative capacity in ACLF without cirrhosis, each prognostic model represents a marked decline of C-index, net reclassification index (NRI), and integrated discrimination improvement (IDI) in predicting either 28-day or 90-day prognosis of patients with cirrhosis. The hazard analysis identified largely overlapping risk factors of poor outcomes in both subgroups, while serum bilirubin was specifically associated with short-term mortality in patients with cirrhosis and blood urea nitrogen in patients without cirrhosis. A subgroup analysis in patients with cirrhosis showed a decline of discrimination of CPMS in those with ascites or infections compared to that in those without. ConclusionPredicting the short-term outcome of HBV-ACLF by CPMs is optimal in patients without cirrhosis but limited in those with cirrhosis, at least partially due to the complicated ascites or infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available